Next Article in Journal
Antimicrobial Peptides Targeting Gram-Positive Bacteria
Next Article in Special Issue
Use of Capsaicin to Treat Pain: Mechanistic and Therapeutic Considerations
Previous Article in Journal
Preparation of Temozolomide-Loaded Nanoparticles for Glioblastoma Multiforme Targeting—Ideal Versus Reality
Previous Article in Special Issue
Targeting TRPM2 in ROS-Coupled Diseases
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2016, 9(3), 55; doi:10.3390/ph9030055

TRPV3 in Drug Development

1
Lilly Research Centre, Eli Lilly and Company Ltd., Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
2
Covance Greenfield Laboratories, Greenfield, Indianapolis, IN 46140, USA
3
Lilly Research Laboratories, Eli Lilly and Company Inc., Indianapolis, IN 46285, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Arpad Szallasi and Susan M. Huang
Received: 1 July 2016 / Revised: 19 August 2016 / Accepted: 31 August 2016 / Published: 9 September 2016
View Full-Text   |   Download PDF [4037 KB, uploaded 9 September 2016]   |  

Abstract

Transient receptor potential vanilloid 3 (TRPV3) is a member of the TRP (Transient Receptor Potential) super-family. It is a relatively underexplored member of the thermo-TRP sub-family (Figure 1), however, genetic mutations and use of gene knock-outs and selective pharmacological tools are helping to provide insights into its role and therapeutic potential. TRPV3 is highly expressed in skin, where it is implicated in skin physiology and pathophysiology, thermo-sensing and nociception. Gain of function TRPV3 mutations in rodent and man have enabled the role of TRPV3 in skin health and disease to be particularly well defined. Pre-clinical studies provide some rationale to support development of TRPV3 antagonists for therapeutic application for the treatment of inflammatory skin conditions, itch and pain. However, to date, only one compound directed towards block of the TRPV3 receptor (GRC15300) has progressed into clinical trials. Currently, there are no known clinical trials in progress employing a TRPV3 antagonist. View Full-Text
Keywords: TRPV3; keratinocytes; itch; pain; Olmsted syndrome TRPV3; keratinocytes; itch; pain; Olmsted syndrome
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Broad, L.M.; Mogg, A.J.; Eberle, E.; Tolley, M.; Li, D.L.; Knopp, K.L. TRPV3 in Drug Development. Pharmaceuticals 2016, 9, 55.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top